Medical termination of a developing intra-uterine pregnancy in sequential combination with a prostaglandin analogue up to 63 days of amenorrhea.
1- Medical termination of developing intra-uterine pregnancy. In sequential use with a prostaglandin analogue, up to 63 days of amenorrhea (see section 4.2) . 2- Softening and dilatation of the cervix uteri prior to surgical termination of pregnancy during the first trimester. 3- Preparation for the action of prostaglandin analogues in the termination of pregnancy for medical reasons (beyond the first trimester) . 4- Labour induction in foetal death in utero. In patients where prostaglandin or oxytocin cannot be used.
Medabon is indicated for medical termination of developing intra-uterine pregnancy of up to 63 days of amenorrhoea.
The objective is to formulate clinical practice guidelines for treating Cushing's syndrome.
The FDA has approved Korlym (mifepristone)(formerly Corlux) from Corcept Therapeutics to control high blood sugar levels (hyperglycemia) in adults with...
• Replacement therapy in congenital adrenal hyperplasia in children. • Treatment of adrenal insufficiency in children and adolescents. • Emergency treatment of severe bronchial asthma, drug hypersensitivity reactions, serum sickness, angioneurotic oedema and anaphylaxis in adults and children.
Ketoconazole HRA is indicated for the treatment of endogenous Cushing's syndrome in adults and adolescents above the age of 12 years.